Fubotv earnings beat by $0.10, revenue topped estimates
On Thursday, Encompass Health Corp (NYSE:EHC) announced that its shareholders approved the 2025 Omnibus Performance Incentive Plan during the Annual Meeting held on May 1, 2025. This development, detailed in the company’s latest 8-K filing with the Securities and Exchange Commission (SEC), reflects the organization’s commitment to aligning the interests of its executives and directors with those of its shareholders. The company, which currently trades near its 52-week high of $117.52 and has demonstrated strong financial health according to InvestingPro analysis, has shown impressive market performance with a 40% return over the past year.
The approved incentive plan is designed to provide performance-based compensation to key company officers, ensuring that their rewards are tied to the company’s success. This alignment appears to be working well, as the company has achieved substantial financial results with revenue of $5.5 billion and a healthy gross profit margin of 42%. In addition to the incentive plan, the stockholders voted on several key proposals, including the election of 10 board members, the ratification of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm, and the approval of compensation for named executive officers.Want deeper insights into Encompass Health’s financial health and valuation? InvestingPro subscribers have access to over 30 additional financial metrics and exclusive analysis.
The election of directors saw all nominated members successfully elected, with a significant majority of the votes cast in favor of each candidate. The stockholders also ratified the appointment of PricewaterhouseCoopers LLP with an overwhelming majority.
The compensation of Encompass Health’s named executive officers, as disclosed in the proxy statement filed on April 1, 2025, received approval from the majority of votes, indicating shareholder satisfaction with the executive compensation structure.
The 2025 Omnibus Performance Incentive Plan received a strong endorsement from the shareholders, passing with a substantial majority. The plan is now set to be a cornerstone of the company’s strategy to incentivize and reward its executives for their performance and contribution to the company’s growth.
The voting results from the Annual Meeting demonstrate a high level of engagement from the shareholders, with votes representing 93.9% of the combined voting power of the common stock being represented by proxy.
Encompass Health, formerly known as HealthSouth Corp , is a leading provider of integrated healthcare services, offering both facility-based and home-based patient care in 34 states across the United States and Puerto Rico. The company has maintained dividend payments for 13 consecutive years, and eight analysts have recently revised their earnings expectations upward for the upcoming period, according to InvestingPro data.
This report is based on a press release statement and provides a factual summary of the key decisions made by the shareholders of Encompass Health Corp during their latest Annual Meeting.
In other recent news, Encompass Health Corporation reported impressive financial results for the first quarter of 2025, surpassing analysts’ expectations with an earnings per share of $1.37, compared to the anticipated $1.20. The company’s revenue also exceeded forecasts, reaching $1.46 billion against the expected $1.43 billion. Following this strong performance, Encompass Health raised its full-year guidance, projecting higher net operating revenue and earnings per share. Analysts from Mizuho (NYSE:MFG) Securities and RBC Capital Markets responded positively to these developments, with Mizuho raising the company’s price target to $130 and RBC increasing it to $125, both maintaining an Outperform rating. The favorable shift in the company’s payer mix, particularly the increase in Medicare Fee-For-Service volumes, was noted as a significant factor in its financial success. Additionally, Encompass Health announced a quarterly dividend of $0.17 per share, reflecting confidence in its financial stability. These recent developments underscore the company’s robust performance and potential for continued growth in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.